I. R. Rodriguez-Chavez

发表

Current advances and challenges in HIV-1 vaccines

J. Bradac, E. Hill, M. Pensiero, 2006, Current HIV/AIDS reports.

Sensing Technologies for Global Health, Military Medicine, and Environmental Monitoring IV

Isaac R. Rodriguez-Chavez, I. R. Rodriguez-Chavez, 2014 .

Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity.

S. Steinberg, R. Yarchoan, G. Tosato, 2007, Critical reviews in immunology.

Recommendations for Defining and Reporting Adherence Measured by Biometric Monitoring Technologies: Systematic Review

Karen L. Fortuna, Abhishek Pratap, J. Bakker, 2021, Journal of medical Internet research.

Human Immunodeficiency Virus (HIV) Vaccine Trials: a Novel Assay for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies

Jerome H. Kim, D. Cooper, R. Bailer, 2006, Journal of Virology.

A pilot study of cidofovir in patients with kaposi sarcoma.

S. Pittaluga, D. Whitby, R. Yarchoan, 2003, The Journal of infectious diseases.

Characterization of the antigenic, immunogenic, and pathogenic variation of infectious bursal disease virus due to propagation in different host systems (bursa, embryo, and cell culture). III. Pathogenicity

C. Pope, I. R. Rodriguez-Chavez, J. Rosenberger, 2002, Avian pathology : journal of the W.V.P.A.

Characterization of the antigenic, immunogenic, and pathogenic variation of infectious bursal disease virus due to propagation in different host systems (bursa, embryo, and cell culture). II. Antigenicity at the epitope level

I. R. Rodriguez-Chavez, J. Rosenberger, S. Cloud, 2002 .

Characterization of the antigenic, immunogenic, and pathogenic variation of infectious bursal disease virus due to propagation in different host systems (bursa, embryo, and cell culture). I. Antigenicity and immunogenicity

I. R. Rodriguez-Chavez, J. Rosenberger, S. Cloud, 2002, Avian pathology : journal of the W.V.P.A.

Characterization of the antigenic, immunogenic, and pathogenic variation of infectious bursal disease virus due to propagation in different host systems (bursa, embryo, and cell culture). I. Antigenicity and immunogenicity.

I. R. Rodriguez-Chavez, J. Rosenberger, S. Cloud, 2002, Avian pathology : journal of the W.V.P.A.

Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.

S. Steinberg, R. Yarchoan, G. Tosato, 2006, Blood.

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.

Allan C. deCamp, S. Self, D. Montefiori, 2010, The Journal of infectious diseases.

Performance of a Redesigned HIV Selectest Enzyme-Linked Immunosorbent Assay Optimized To Minimize Vaccine-Induced Seropositivity in HIV Vaccine Trial Participants

Michael P. Busch, Eric Hunter, Robert J. O'Connell, 2014, Clinical and Vaccine Immunology.

HIV-Selectest Enzyme Immunoassay and Rapid Test: Ability To Detect Seroconversion following HIV-1 Infection

J. Margolick, B. Haynes, F. Hecht, 2009, Journal of Clinical Microbiology.

Considerations for Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials

B. Ratitch, Stuart Morton, B. Vandendriessche, 2022, Digital Biomarkers.

Empowering clinical research in a decentralized world

C. Patel, N. Shah, A. Manrai, 2021, npj Digital Medicine.

Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials

Marcella Sarzotti-Kelsoe, T. Denny, Daniel A. Ozaki, 2009, PLoS medicine.

Rigorous and rapid evidence assessment in digital health with the evidence DEFINED framework

P. Wicks, V. Willey, J. Carl, 2023, npj Digit. Medicine.

Verification, analytical validation and clinical validation (V3) of wearable dosimeters and light loggers

K. Smolders, C. Vetter, J. Bakker, 2022, Digital health.

Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories.

J. Darden, M P D'Souza, J Ezzelle, 2008, Journal of pharmaceutical and biomedical analysis.

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.

Allan C. deCamp, S. Self, D. Montefiori, 2010, The Journal of infectious diseases.

Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials

Daniel A. Ozaki, J. Hural, G. Stevens, 2009, PLoS medicine.